Nitrofurantoin Activase Pharmaceuticals (Nitrofurantoin)

Nitrofurantoin is reduced inside bacterial cells to reactive intermediates that damage DNA, ribosomal proteins and enzymes involved in carbohydrate metabolism. This multi‑target attack disrupts essential bacterial processes, leading to rapid bactericidal activity against common uropathogens.

The dosage of Nitrofurantoin Activase is determined by the prescribing clinician based on the patient’s condition, renal function and local guidelines. Only a qualified healthcare professional should set the appropriate dose and treatment duration.

The safety of nitrofurantoin in pregnancy is not fully established; it is generally avoided in the first trimester and near term. Use while breastfeeding should be considered only if the benefit outweighs potential risk, and under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nitrofurantoin is distinct from fluoroquinolones and trimethoprim‑sulfamethoxazole because it concentrates in urine and has a narrow spectrum focused on common uropathogens. It is often preferred for uncomplicated cystitis when resistance to other agents is a concern, though it is not suitable for systemic infections.

Store Nitrofurantoin Activase at room temperature, below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Nitrofurantoin Activase is taken orally, usually with food or a full glass of water to improve absorption and reduce gastrointestinal irritation. The exact dosing schedule should follow the prescriber’s instructions.

Serious adverse events include pulmonary toxicity (interstitial lung disease or acute pneumonitis), hepatic injury, hemolytic anemia in patients with G6PD deficiency, severe allergic reactions such as anaphylaxis, and peripheral neuropathy. Prompt medical attention is required if any of these occur.

Nitrofurantoin should be avoided in patients with severe renal impairment (creatinine clearance <60 mL/min), known hypersensitivity to nitrofurantoin or other nitrofurans, G6PD deficiency (due to risk of hemolysis), and in late pregnancy unless specifically indicated by a physician.